Pharmacokinetics of loratadine in patients with renal insufficiency.
The disposition of loratadine, a new orally active histamine H1 receptor antagonist and its primary metabolite descarboethoxyloratadine were characterized in adult volunteers with normal renal function (group I), patients with chronic renal failure, i.e., creatinine clearance less than 30 mL/min (group II), as well as chronic hemodialysis patients (group III). The effect of hemodialysis on the disposition of loratadine and descarboethoxyloratadine was also assessed. Subjects in groups I and II were given a single oral 40 mg dose of loratadine while the patients in Group III received two single 40 mg doses of loratadine (during an interdialytic period and just prior to hemodialysis). Loratadine was rapidly absorbed and the decline of plasma concentrations after attainment of the Cmax was biexponential in all subjects. No significant differences in t1/2 beta were observed between the three groups (8.7 +/- 5.9, 7.6 +/- 6.9, 8.6 +/- 1.6 hrs: in groups I, II, and III, respectively). The apparent total body clearance and apparent volume of distribution of loratadine also did not differ significantly among the three groups. No significant differences in the Cmax or tmax of the metabolite were observed. The metabolite AUC infinity 0 however was significantly greater in group II subjects: (212.4 +/- 37.8, 469.5 +/- 95.4, 325.2 +/- 114.6 ng.hr/mL; groups I, II, and III, respectively). No significant relationship was observed between the terminal elimination half-life of loratadine or descarboethoxyloratadine and creatinine clearance. Hemodialysis augmented endogenous clearance by less than 1%. The disposition of loratadine is not significantly altered in patients with severe renal insufficiency nor is hemodialysis an effective means of removing loratadine or descarboethoxyloratadine from the body.
Matzke
G R
GR
Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415.
Halstenson
C E
CE
Opsahl
J A
JA
Hilbert
J
J
Perentesis
G
G
Radwanski
E
E
Zampaglione
N
N
D000328:Adult; D003533:Cyproheptadine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D017336:Loratadine / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000493:pharmacokinetics*; D011725:Pyridines / Q000493:pharmacokinetics*; D006435:Renal Dialysis; D013997:Time Factors
D010880:Piperidines; D011725:Pyridines; D003533:Cyproheptadine; D017336:Loratadine; C121345:desloratadine